Park Place Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Park Place Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-37	Closed	-$1.63K	–	868
2025 Q1	$1.63K	Buy	+37	New	+$1.7K	﹤0.01%	753
2024 Q4	–	Sell	-28	Closed	-$897	–	872
2024 Q3	$897	Hold	28	–	–	﹤0.01%	831
2024 Q2	$1.05K	Hold	28	–	–	﹤0.01%	829
2024 Q1	$1.38K	Buy	+28	New	+$1.29K	﹤0.01%	866
2023 Q4	–	Sell	-24	Closed	-$555	–	1012
2023 Q3	$555	Hold	24	–	–	﹤0.01%	1001
2023 Q2	$629	Hold	24	–	–	﹤0.01%	1001
2023 Q1	$618	Hold	24	–	–	﹤0.01%	1001
2022 Q4	$1K	Buy	+24	New	+$591	﹤0.01%	1019

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Park Place Capital's SWTX Position: Q2 2025 in Review

Park Place Capital sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 37 shares — an estimated $1.63K sold.

Park Place Capital first reported a position in SWTX in Q4 2022 and held it in 8 quarters. The position peaked at $1.63K in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Park Place Capital reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Park Place Capital sold 37 SpringWorks Therapeutics shares in Q2 2025, an estimated $1.63K.
Park Place Capital first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 8 quarters.
Park Place Capital's SpringWorks Therapeutics position peaked at $1.63K in Q1 2025.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Park Place Capital's 13F filing for Q2 2025, filed 17 Jul 2025.